CanImmunother API

The API interface can be invoked by user using a broad range of programming languages (python, Java, etc.), and all association data can be retrieved by providing the association identifier (ID) in CanImmunother, e.g. CANIT0000004.

Example url: www.biomedical-web.com/cancerit/cancerit/association?ass_id=CANIT0000080

Optional parameter: Association identifier (string)---This is the association identifier(ID) in CanImmunother, e.g. CANIT0000004.

The output data is available in the universal JSON format

{"Results":[{"ass_id":"CANIT0000081","pmid":"20466887","res_type":"Clinical research","sample":"HER-2/neu(+) prostate cancer","disease":"Prostate cancer","efo":"MONDO:0008315","position":"Prostate","uniprotid":"HER2 (P04626); ","target":"HER2; ","treatment":"AE36 vaccine","control":"N/A","treat_type":"Vaccine","drugs":"AE36 vaccine (NCIT:C2537); ","sample_size_treat":"32","sample_size_con":"N/A","design":"A phase I clinical trial ","clinical":"AE37 vaccine is safe and can induce HER-2/neu-specific cellular immune responses in patients with castrate-sensitive and castrate-resistant prostate cancer, thus emphasizing the potential of AE37 to target HER-2/neu for the immunotherapy of prostate cancer.  Additionally, significant decreases could be detected in circulating Treg frequencies, plasma HER-2/neu, and serum transforming growth factor-beta levels. Patients with less extensive disease developed better immunologic responses on vaccination.","event":"Toxicities beyond grade 2 were not observed. ","cell_evidence":"N/A","animal_model":"N/A","biomarkerid":"Treg cells (CL:0000815); T-Lymphocyte (NCIT:C12476); ","biomarker":"Circulating Treg frequencies","biomarker_type":"Cell percentage/counts in blood","year":" 2010 Jul 1","title":" Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790)  hybrid peptide vaccine in patients with prostate cancer.","journal":" Clin Cancer Res","abstract_p":" PURPOSE: Active immunotherapy is emerging as a potential therapeutic approach for  prostate cancer. We conducted the first phase I trial of an  Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine (AE37) with recombinant  granulocyte macrophage colony-stimulating factor as adjuvant in patients with  HER-2/neu(+) prostate cancer. The primary end points of the study were to  evaluate toxicity and monitor patients' immune responses to the vaccine.  EXPERIMENTAL DESIGN: Thirty-two HER-2/neu(+), castrate-sensitive, and  castrate-resistant prostate cancer patients were enrolled. Of these, 29 patients   completed all six vaccination cycles with AE37. Immunologic responses in the  total patient population were monitored by delayed-type hypersensitivity and  IFN-gamma ELISPOT and intracellular staining. Regulatory T-cell (Treg) frequency   and plasma HER-2/neu and transforming growth factor-beta levels were also  determined. Immunologic responses were also analyzed among groups of patients  with different clinical characteristics. Local/systemic toxicities were monitored  throughout the study. RESULTS: Toxicities beyond grade 2 were not observed.  Seventy-five percent of patients developed augmented immunity to the AE37 vaccine  and 65% to the unmodified AE36 peptide as detected in the IFN-gamma-based ELISPOT  assay. Intracellular IFN-gamma analyses revealed that AE37 elicited both CD4(+)  and CD8(+) T-cell responses. Eighty percent of the patients developed a positive   delayed-type hypersensitivity reaction to AE36. Additionally, significant  decreases could be detected in circulating Treg frequencies, plasma HER-2/neu,  and serum transforming growth factor-beta levels. Patients with less extensive  disease developed better immunologic responses on vaccination. CONCLUSION: AE37  vaccine is safe and can induce HER-2/neu-specific cellular immune responses in  patients with castrate-sensitive and castrate-resistant prostate cancer, thus  emphasizing the potential of AE37 to target HER-2/neu for the immunotherapy of  prostate cancer."}]}